MPJX-594

MPJX-594 (mpJX) is a mouse-adapted oncolytic vaccinia virus derived from the Western Reserve (WR) strain. It is engineered with the same plasmid design as the clinical-stage oncolytic virus Pexa-Vec (pexastimogene devacirepvec), featuring a disruption of the viral thymidine kinase (TK) gene and expression of the human granulocyte-macrophage colony-stimulating factor (hGM-CSF) transgene. MPJX-594 is designed to selectively replicate in tumor cells and stimulate an antitumor immune response. Preclinical studies in pancreatic neuroendocrine tumor (PanNET) models demonstrate that intravenous administration of MPJX-594, particularly in combination with PD-1 checkpoint blockade, promotes significant influx of CD8+ T cells and natural killer (NK) cells, induces tumor cell apoptosis, suppresses proliferation, and reduces metastatic burden.

Other names

mouse-adapted Pexa-VecWR-hGM-CSF-TK-